Oral Immunotherapy in Food Allergy in Finland

Overview

The outcomes of oral immunotherapy (OIT) in food allergy study will provide more knowledge of oral immunotherapy. So far the OIT has showed in clinical experiments to be a interesting way to increase the unresponsiveness in severe food allergies. However little is known about it´s long-term outcomes, immunological mechanisms and there are no previous studies about cost-utility of OIT.

Full Title of Study: “Specific Oral Immunotherapy in Food Allergy – Real-life Long-term Follow up (After Milk Oral Immunotherapy), Effect on Health-related Quality of Life and Cost-utility Analyses”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2021

Detailed Description

The purpose of the present study is to examine the outcomes of the food oral immunotherapy on patients with severe food allergy in the three different subprojects: Study 1: Long-term follow up after milk oral immunotherapy. The measured outcomes are long-term effectiveness (e.g. health-related quality of life), safety of desensitization and immunological changes. Study 2: Measure health-related quality of life with disease-specific and generic questionnaire. The aim of this study is to define the suitability of the FAQLQ and the 15-D questionnaires for the Finnish food allergic patients. Another purpose of this study is to examine the relationship between FAQLQ and 15-D questionnaires. Study 3: QALYs. This is called the cost-utility analyses and QALYs and its purpose is to calculate the cost of OIT and to define the cost-effectiveness of OIT by measuring QALYs. To our knowledge this will be the first pilot study to define the QALYs in food oral immunotherapy. The aim is to have 50-100 patients. The literature in other areas of medicine 50-100 patients in QALY-publishing is quite plain.

Interventions

  • Dietary Supplement: Milk
    • Milk Oral immunotherapy

Arms, Groups and Cohorts

  • Experimental: Study 1: Milk OIT follow up
    • Follow up on patient with severe milk allergy how have participated to milk OIT.
  • No Intervention: Study 1: Follow up
    • Follow up on patient with severe milk allergy how have not participated to milk OIT.

Clinical Trial Outcome Measures

Primary Measures

  • Long-term effectiveness as a measure of milk consumption (dl/day).
    • Time Frame: Ten years
    • Consumption of milk (dl/day)

Secondary Measures

  • General health-related quality of life
    • Time Frame: One year
    • To measure health-related quality of life by using a generic (Finnish 15-D questionnaire) before and one year after OIT.
  • Disease specific health-related quality of life
    • Time Frame: One year
    • To measure health-related quality of life by using a disease specific questionnaires (Food Allergy Quality of Life Questionnaires, FAQLQ) before and one year after OIT.
  • Cost-utility analysis and health benefits by measuring quality-adjusted life-years (QALYs).
    • Time Frame: One year
    • A Pilot study to define the cost of OIT and define the cost of quality-adjusted life-years (QALYs) with generic health-realted quality of life scale 15-D-questionnaire.
  • Incidence of Treatment – Emergent Adverse Events
    • Time Frame: Ten years
    • Severe adverse events

Participating in This Clinical Trial

Inclusion Criteria

  • Study 1: All the children have been eligible to participate milk OIT during the years 2005-2015. – Study 2 + 3: Patients will start OIT treatment (to milk / egg / peanut). Exclusion Criteria:

  • Not willing to participate – Active asthma, low lung function, pregnancy, cardiovascular or other disease that might worsen during the OIT.

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Helsinki University Central Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Tiina Kauppila, MD, MD – Helsinki University Central Hospital
  • Overall Official(s)
    • Mika J Mäkelä, MD, PhD, Study Director, Chief Physician, Helsinki University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.